Vol. 5 No. 2 (2025), Original Articles
Vol. 5 No. 2 (2025)

Predictive factors of relapses after medical treatment of Graves’ disease in Ivory Coast.

Original Articles
https://doi.org/10.67869/952evb30 Crossmark
Published 2025-12-30
I Mato
Service d’Endocrinologie-Diabétologie, CHU de Yopougon, Abidjan, (Côte d’Ivoire).
A Yao
Service d’Endocrinologie-Diabétologie, CHU de Yopougon, Abidjan, (Côte d’Ivoire).
I Ousmane
Service de Cardiologie de l’Hôpital national de Zinder (Niger)
H Moussa
Service de Dermatologie de l’Hôpital régional de Dosso (Niger)
R Mahaman Yacoubou Abdoul
Laboratoire clé de la province du Hubei pour l'étude et le traitement des maladies rénales, faculté de médecine, université polytechnique du Hubei, Huangshi (Chine)
S Ousmane
Services de Dermatologie Hôpital national de Niamey (Niger).
J Abodo
Service d’Endocrinologie-Diabétologie, CHU de Yopougon, Abidjan, (Côte d’Ivoire).
PDF (French)

Keywords

Basedow
récidive
score GREAT
Côte d’Ivoire

How to Cite

1.
Mato I, Yao A, Ousmane I, Moussa H, Mahaman Yacoubou Abdoul R, Ousmane S, et al. Predictive factors of relapses after medical treatment of Graves’ disease in Ivory Coast. J Sah Sci Santé [Internet]. 2025 Dec. 30 [cited 2026 Oct. 14];5(2):1559-67. Available from: https://www.j3s-fss-uas.org/index.php/jsss/article/view/196
ABNT ACM ACS AMA APA Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Introduction :
Recurrence of Graves' disease treated with synthetic antithyroid drugs is frequent. The identification and evaluation of recurrence risk markers are necessary to optimize management. The objective of this work was to study the factors of Graves' disease recurrence at the Yopougon University Hospital (CHU) in Côte d'Ivoire. Materials and Methods : This was an analytic study with retrospective data collection conducted from January 2002 to December 2018 (17 years), including 239 patients treated with synthetic antithyroid drugs for a first episode of Graves' disease. Socio-epidemiological, clinical, biological, therapeutic, and evaluative data were collected.

Results :
Out of 239 patients, 18.41% (n = 44) presented with a recurrence. The mean age was 32.6 ± 13 years, with a female predominance (72.72%; n = 32). The 16–30 age group was the most represented (52.27%; n = 23). Malignant exophthalmos was the only factor significantly associated with recurrence (p<0.05). The other factors studied were not significantly associated. The GREAT score proved to be poorly discriminatory in our study.

Conclusion :
The recurrence rate is 18.41%. Malignant exophthalmos was the only independent risk marker for recurrence found. The use of the GREAT score seems inapplicable in this context.

PDF (French)
References

1. Lanzolla G, Marinò M, Menconi F. Graves disease: latest understanding of pathogenesis and treatment options. Nat Rev Endocrinol. 2024;20(11):647-60.

2. Hoang TD, Stocker DJ, Chou EL, Burch HB. 2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease. Endocrinol Metab Clin North Am. 2022;51(2):287-304.

3. Struja T, Fehlberg H, Kutz A, Brodmann Maeder M, Melmer A, Meier C, et al. Can we predict relapse in Graves’ disease? Results from a prospective multicenter study. Eur J Endocrinol. 2017;176(1):87-97.

4. Vos XG, Smit N, Endert E, Tijssen JG, Wiersinga WM. Pattern and predictors of recurrence of Graves' hyperthyroidism after antithyroid drug treatment. Eur J Endocrinol. 2016 May;174(5):653-62.

5. Philippe J. La maladie de Basedow. Rev Med Suisse. 2009;5(204):764-8.

6. Weetman AP. Graves’ disease. N Engl J Med. 2000;343(17):1236-48.

7. Sturny Z, Struja T, Cornelius J, Müller B, Schuetz P. Nouvel outil décisionnel dans le traitement de la maladie de Basedow. Rev Med Suisse. 2018;14(607):1014-8.

8. Tatishvili S, Buffet C. Nouvelles perspectives pour le diagnostic et le pronostic de la maladie de Basedow. Ann Endocrinol (Paris). 2018;79(Suppl 1):S31-9.

9. Ben Othman R, Yazidi M, Rejeb O, Chaker F, Chihaoui M, Slimene H, et al. Facteurs de risque de rechutes de la maladie de Basedow traitée par antithyroïdiens de synthèse. Ann Endocrinol (Paris). 2016;77(4):383-8.

10. Bouziane T, Larwanou MM, Elouahabi H. Facteurs prédictifs de rechute de la maladie de Basedow traitée par antithyroïdiens de synthèse : à propos de 72 cas. Ann Endocrinol (Paris). 2017;78(4):331-6.

11. Yao A, Ahoussi JB, Koffi D, Hue A, Danho J, Abodo J, et al. Aspects thérapeutiques et évolutifs de la maladie de Basedow à l’Hôpital Militaire d’Abidjan (Côte d’Ivoire). Health Sci Dis. 2020;21(3):71-6.

12. Abdelkerim M. Schéma « Block and Replace » dans la prise en charge de la maladie de Basedow au service d’endocrinologiediabétologie du CHU de Yopougon d’Abidjan [Mémoire de DES]. Abidjan : Université Félix Houphouët-Boigny; 2020.

13. Sana M. Maladie de Basedow : aspects épidémiologiques, cliniques, thérapeutiques et évolutifs [Thèse de médecine]. Dakar: Université Cheikh Anta Diop; 2015.

14. Diop S, Halim A, Leye A, Ka MM. Aspects psychoaffectifs et manifestations psychiatriques dans la maladie de Basedow : à propos de 104 cas au Sénégal. Rev CAMES Sante. 2011;12:62-4.

15. Coulet O, Kraemer P, Leyral G, Cloatre G. Prise en charge de la maladie de Basedow en milieu tropical : expérience du CHA Bouffard (Djibouti). Med Trop (Mars). 2004;64(2):192-4.

16. Wiersinga WM. Graves’ disease: can it be cured? Endocrinol Metab (Seoul). 2019;34(1):29-38.

17. Effraimidis G. Predictive scores in autoimmune thyroid disease: are they useful? Eur J Endocrinol. 2019;181(3):R125-36.

Metrics

Downloads

Download data is not yet available.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2025 I Mato, A Yao, I Ousmane, H Moussa, R Mahaman Yacoubou Abdoul, S Ousmane, J Abodo